Latest Familial amyloid neuropathy Stories
Up to 92 percent reduction in transthyretin protein in patients with familial amyloid polyneuropathy CARLSBAD, Calif., April 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- LUNAR-101, an UNA(TM) oligomer therapeutic for transthyretin-mediated familial amyloid cardiomyopathy (TTR-FAC), exhibited in non-human primates TTR reduction greater than 90% with a single low dose
- Greater than 100-fold Allele-specific silencing of V30M variant for the treatment of Familial Amyloid Polyneuropathy (TTR-FAP) - SAN DIEGO, May 13, 2014 /PRNewswire/ --
CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel®) works.
CARLSBAD, Calif., May 19, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.
- An armed gangster.